According to American Cancer Society, more than 44,000 new cases of pancreatic cancer will be giagnosed in the U.S. and over 37,000 deaths are expected in 2011.
Approved Drugs:
Single agent:
Gemzar [gemcitabine] : Eli Lilly (LLY), single agent, approved in1997 for locally advanced or metastatic panreatic exocrine cancer. Median OS: 5.7 months, one-year probability of survival rate: 18%.
Combination agents:
Gemzar [gemcitabine] plus Tarceva [erlotinib] from Roche/Astellas Parma, the only successful combination approved by the FDA in 2005. Median OS: 6.4 months, one-year survival rate: 23%.
From: 13 Drug Companies Trying to Beat the Odds in Pancreatic Cancer
Approved Drugs:
Single agent:
Gemzar [gemcitabine] : Eli Lilly (LLY), single agent, approved in1997 for locally advanced or metastatic panreatic exocrine cancer. Median OS: 5.7 months, one-year probability of survival rate: 18%.
Combination agents:
Gemzar [gemcitabine] plus Tarceva [erlotinib] from Roche/Astellas Parma, the only successful combination approved by the FDA in 2005. Median OS: 6.4 months, one-year survival rate: 23%.
From: 13 Drug Companies Trying to Beat the Odds in Pancreatic Cancer
